Commodore Capital LP
- SEC CIK
- 0001831942
- Latest filing
- Aug 14, 2026
Holdings in Q3 2022
Holdings as of Sep 30, 2022, filed Nov 14, 2022. Long positions only; changes compare share counts with Q2 2022.
- Positions
- 30
- +6 vs. Q2 2022
- Portfolio value
- $621.9M
- +$148.9M (+31.5%) vs. Q2 2022
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| COGTCogent Biosciences, Inc. | COM | 4,319,940 | $64.5M | 10.4% | −624,768−12.6% | Reduced | History |
| XENEXenon Pharmaceuticals Inc. | COM | 1,594,932 | $57.6M | 9.3% | 00.0% | Unchanged | History |
| VRDNViridian Therapeutics, Inc. | COM | 2,696,340 | $55.3M | 8.9% | +1,057,731+64.6% | Added | History |
| Bellus Health Inc New07987C204 | COM NEW | 5,128,557 | $54.2M | 8.7% | +648,773+14.5% | Added | – |
| MRUSMerus N.V. | COM | 2,615,762 | $52.4M | 8.4% | 00.0% | Unchanged | History |
| CYTKCytokinetics Inc | COM NEW | 893,646 | $43.3M | 7.0% | 00.0% | Unchanged | History |
| ACRSAclaris Therapeutics, Inc. | COM | 2,410,622 | $37.9M | 6.1% | 00.0% | Unchanged | History |
| AKROAkero Therapeutics, Inc. | COM | 743,472 | $25.3M | 4.1% | +743,472 | New | History |
| STSASatsuma Pharmaceuticals, Inc. | COM | 3,711,286 | $22.3M | 3.6% | 00.0% | Unchanged | History |
| TCDATricida, Inc. | COM | 1,975,403 | $20.7M | 3.3% | −53,050−2.6% | Reduced | History |
| CBAYCymaBay Therapeutics, Inc. | COM | 5,738,500 | $20.1M | 3.2% | 00.0% | Unchanged | History |
| THRDThird Harmonic Bio, Inc. | COM | 1,018,569 | $19.3M | 3.1% | +1,018,569 | New | History |
| SNDXSyndax Pharmaceuticals Inc | COM | 738,110 | $17.7M | 2.9% | +738,110 | New | History |
| CLDXCelldex Therapeutics, Inc. | COM NEW | 538,812 | $15.1M | 2.4% | 00.0% | Unchanged | History |
| DAWNDay One Biopharmaceuticals, Inc. | Stock | 739,661 | $14.8M | 2.4% | 00.0% | Unchanged | History |
| ARWRArrowhead Pharmaceuticals, Inc. | COM | 404,078 | $13.4M | 2.1% | +91,545+29.3% | Added | History |
| KURAKura Oncology, Inc. | COM | 899,407 | $12.3M | 2.0% | −927,084−50.8% | Reduced | History |
| ABOSAcumen Pharmaceuticals, Inc. | COM | 1,100,000 | $11.0M | 1.8% | +1,100,000 | New | History |
| KPTIKaryopharm Therapeutics Inc. | COM | 1,935,609 | $10.6M | 1.7% | 00.0% | Unchanged | History |
| ALLKAllakos Inc. | COM | 1,643,500 | $10.1M | 1.6% | +1,643,500 | New | History |
| ALPNAlpine Immune Sciences, Inc. | COM | 1,325,000 | $9.54M | 1.5% | +1,325,000 | New | History |
| CELCCelcuity Inc. | COM | 920,464 | $9.24M | 1.5% | 00.0% | Unchanged | History |
| ENTAEnanta Pharmaceuticals Inc | COM | 103,494 | $5.37M | 0.9% | +103,494 | New | History |
| KALVKalVista Pharmaceuticals, Inc. | COM | 312,553 | $4.54M | 0.7% | 00.0% | Unchanged | History |
| RZLTRezolute, Inc. | COM NEW | 1,210,000 | $3.31M | 0.5% | 00.0% | Unchanged | History |
| ESPREsperion Therapeutics, Inc. | COM | 467,468 | $3.13M | 0.5% | +467,468 | New | History |
| IMUXImmunic, Inc. | COM | 893,013 | $2.82M | 0.5% | 00.0% | Unchanged | History |
| BCLS Acquisition CorpG0904B105 | COM CL A | 250,000 | $2.50M | 0.4% | 00.0% | Unchanged | – |
| LRMRLarimar Therapeutics, Inc. | COM | 750,000 | $2.40M | 0.4% | +750,000 | New | History |
| TERNTerns Pharmaceuticals, Inc. | COM | 205,870 | $1.21M | 0.2% | +205,870 | New | History |
Sold out since Q2 2022 (4)
Positions held at the end of Q2 2022 that are gone from this filing.
| Security | Class | Shares in Q2 2022 | Value in Q2 2022 | % of portfolio in Q2 2022 | History |
|---|---|---|---|---|---|
| ISEEIVERIC bio, Inc. | COM | 2,409,961 | $23.2M | 4.9% | History |
| VTGNVistagen Therapeutics, Inc. | COM NEW | 13,049,079 | $11.5M | 2.4% | History |
| TNYATenaya Therapeutics, Inc. | COM | 357,699 | $2.01M | 0.4% | History |
| IVAInventiva S.A. | ADS | 175,500 | $995.0K | 0.2% | History |